InnoCare Pharma
Manufacturing · New Jersey, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
103 Carnegie Ctr Ste 209, Princeton, New...Phone Number
(609) 524-0673Website
www.innocarepharma.comRevenue
$32.5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About InnoCare Pharma
诺诚健华 is focused on developing innovative drugs to address significant unmet clinical needs in the fields of malignant tumors and autoimmune diseases. The company possesses comprehensive research and commercialization capabilities, aiming to create first-in-class or best-in-class therapies for global markets. With a strong pipeline in hematological malignancies, autoimmune diseases, and solid tumors, 诺诚健华 is committed to delivering high-quality innovative medicines that benefit patients worldwide. The company is led by co-founder and CEO Dr. 崔霁松, who emphasizes the importance of scientific-driven innovation.Explore more
InnoCare Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is InnoCare Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when InnoCare Pharma launches new products
InnoCare Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check if InnoCare Pharma has recently received funding, and reach out quickly before it becomes old news!
Check out if InnoCare Pharma is spiking on competitors!
Funding: Get notified immidiatlly once InnoCare Pharma has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on InnoCare Pharma recently announced quarterly report
Click to see if InnoCare Pharma had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at InnoCare Pharma
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at InnoCare Pharma
Find 2 more new buyers
Compare Similar Companies to InnoCare Pharma
Compare insights from companies similar to InnoCare Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
InnoCare Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
InnoCare Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about InnoCare Pharma.
InnoCare Pharma financials insights
Gather financial insights about InnoCare Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Stock Offering
$288M
InnoCare Pharma Tech Stack
A closer look at the technologies used by InnoCare Pharma
Most Recent Scoops
Project
Research & Development, Intellectual Property, Legal Affairs, Medical Research, Pharmaceuticals
Person-Based
Person-Based
Person-Based
Project
Research & Development, Compliance, Medical Research, Pharmaceuticals, Regulations
InnoCare Pharma News & Media
InnoCare Announces Phase II Study Results of TYK2 Inhibitor Soficitinib Meet Primary Endpoint in Patients with Vitiligo
BEIJING, July 16, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Phase II portion of the Phase II/III trial of its TYK2 inhibitor Soficitinib (ICP-332) for non-segmental vitiligo has met the primary endpoint.InnoCare Announces Phase III Study Results of TYK2 Inhibitor Soficitinib Meet Primary Endpoint in Patients with Atomic Dermatitis
BEIJING, July 15, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that registrational phase III clinical study results of novel TYK2 (Tyrosine Kinase 2) inhibitor soficitinib (ICP-332) met the primary endpoint in patients with moderate-to-severe atopic dermatitis (AD).InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL
The paper in STTT concludes that orelabrutinib significantly prolongs PFS and reduces the risk of disease progression or death by 68%.Study Results of Orelabrutinib in Patients with SLE Published in the Journal of Autoimmunity
Orelabrutinib is the first BTK inhibitor globally to demonstrate efficacy in a Phase II clinical trial for SLE.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding InnoCare Pharma
Sign Up For FreeTo access detailed company insights
诺诚健华 is focused on developing innovative drugs to address significant unmet clinical needs in the fields of malignant tumors and autoimmune diseases. The company possesses comprehensive research and commercialization capabilities, aiming to create first-in-class or best-in-class therapies for global markets. With a strong pipeline in hematological... Read More
